Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$18.37M | 2 yrs ago

About IMB Dx

IMB Dx develops AlphaLiquid, a liquid biopsy test for the blood-based early detection of cancer. AlphaLiquid detects cancer by analyzing the minute ctDNA (circulating tumor DNA), in turn providing targeted gene results that can help direct therapy selection and clinical trial options for advanced-stage cancer patients.

Headquarters Location

131, Gasan digital 1-ro, Geumcheon-gu 20F, Bldg A, BYC Highcity

Seoul, 08506,

South Korea

Missing: IMB Dx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IMB Dx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing IMB Dx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned IMB Dx in 1 CB Insights research brief, most recently on Feb 15, 2022.

Expert Collections containing IMB Dx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IMB Dx is included in 5 Expert Collections, including Cancer.



3,710 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,901 items

Latest IMB Dx News

Cancer Tumor Profiling Global Market Report 2022

Jun 15, 2022

" - , NanoString, NeoGenomics Laboratories, Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation (Genomic Health Inc.), Guardant Health, and Foundation Medicine Inc. The global cancer tumor profiling market is expected to grow from $8.16 billion in 2021 to $9.58 billion in 2022 at a compound annual growth rate (CAGR) of 17.5%. The cancer tumor profiling market is expected to grow to $15.96 billion in 2026 at a CAGR of 13.6%. The cancer tumor profiling market consists of sales of cancer tumor profiling technologies by entities (organization, partnership, sole traders) that refer to a laboratory test that examines a sample of tumor tissue for specific genes or gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body. The main types of cancer and tumor profiling are lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and other cancer types.The different technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarray, and other technologies and involve various processes types such as genomics, proteomics, epigenetics, metabolomics, others. It is used in several applications including personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. North America was the largest region in cancer and tumor profiling market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The increasing incidences of cancer across the globe are expected to propel the growth of cancer and tumor profiling market going forward.Cancer is a disease in which some cells in the body get uncontrollably large and spread to other parts of the body. As the number of cancer cases rises, so does the demand for cancer tumor profiling, which enables doctors to determine the severity of the disease. For instance, according to the World Health Organization (WHO), there are a 19.3 million increase in cancer cases in 2020, with over 10 million fatalities worldwide. Among these new cases, lung and breast cancer accounted for 23.1% of all cancer cases. In addition, according to the International Agency for Research on Cancer (IARC), 1 in 5 individuals will develop cancer during their lifetime, and 1 in 11 women and 1 in 8 men will die from it. Therefore, the increasing incidences of cancer across the globe drive the growth of the cancer and tumor profiling market. The increasing research and development activities have emerged as the key trend gaining popularity in the cancer and tumor profiling market.Major companies operating in the cancer and tumor profiling sector are focused on research and development activities to meet consumer demand and reinforce their position. For instance, in February 2020, QIAGEN N.V, a German company that develops sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe as a tool to help identify breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic assay for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and first to allow testing of both DNA from plasma specimens or FFPE tissue. In July 2021, Labcorp, a US-based clinical laboratory-acquired OmniSeq for an undisclosed amount.The acquisition enables Labcorp to expand its array of clinical trial options and diagnostic tests for cancer patients and doctors. OmniSeq is a US-based company involved in solid tumor profiling that controls new sequencing technologies and supports drug development through pharmaceutical services. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

IMB Dx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

IMB Dx Rank

IMB Dx Frequently Asked Questions (FAQ)

  • When was IMB Dx founded?

    IMB Dx was founded in 2018.

  • Where is IMB Dx's headquarters?

    IMB Dx's headquarters is located at 131, Gasan digital 1-ro, Geumcheon-gu, Seoul.

  • What is IMB Dx's latest funding round?

    IMB Dx's latest funding round is Series B.

  • How much did IMB Dx raise?

    IMB Dx raised a total of $25.45M.

  • Who are the investors of IMB Dx?

    Investors of IMB Dx include BSK Investment, InterVest, Partners Investment, Gabmar Vitae, Samho Green Investment and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.